Clinical significance of antinuclear antibodies in primary immune thrombocytopenia

There are discrepancies across guidelines about whether the dosage of antinuclear antibodies (ANAs) is of use at the diagnosis of primary immune thrombocytopenia (ITP). This review describes the current knowledge about ANA prevalence in patients with primary ITP, and their potential usefulness as biomarkers for ITP evolution, response to treatments and increased risk of subsequent development of systemic lupus and thrombosis.

Automated summary

There is inconsistency in guidelines regarding the usefulness of antinuclear antibodies (ANAs) dosage in the diagnosis of primary immune thrombocytopenia (ITP). This review provides an overview of the current understanding of ANA prevalence in patients with primary ITP and their potential role as biomarkers for ITP progression, treatment response, and increased risk of developing systemic lupus and thrombosis.